1 / 26

CONTRACEPTIVE AND PRO-FERTILITY AGENTS

CONTRACEPTIVE AND PRO-FERTILITY AGENTS. Yulia Komarova , Ph.D. ykomarov@uic.edu. Control of the Menstrual Cycle. Neuroendocrine control of gonadotropin secretion. Contraceptives. Oral contraceptives: 1. Combination contraceptives – contain both estrogenic and progestogenic agents

diedrick
Download Presentation

CONTRACEPTIVE AND PRO-FERTILITY AGENTS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. CONTRACEPTIVE AND PRO-FERTILITY AGENTS YuliaKomarova, Ph.D. ykomarov@uic.edu

  2. Control of the Menstrual Cycle

  3. Neuroendocrine control of gonadotropin secretion

  4. Contraceptives Oral contraceptives: 1. Combination contraceptives – contain both estrogenic and progestogenic agents • Monophasic • Multiphasic • Biphasic • Triphasic 2. Progestin-Only contraceptives, “minipill” - continuous use of progestin only Other contraceptives: • ORHTO EVRA – transdermal (both estrogenic and progestogenic) • NUVARING – hormone-releasing intravaginal ring (both hormones) • DMPA – injection of progestin • IMPLANON and NORPLANT II- implantable progestin only • IUD and MIRENA – insert and an intrauterine device - progestin only

  5. Contraceptive Agents

  6. Contraceptive Agents

  7. Mechanism of Action • Combination contraceptives • prevent ovulation • selectively suppress FSH and LH secretion and depresses ovarian function; • decreases chance of conception and implantation secondary to changes in the cervical mucus and uterine endometrium • Progestin-Only Contraceptives • prevent ovulation only 60-80% of cycles • cause a thickening of cervical mucus and prevent sperm penetration • cause endometrial alterations that impair implantation

  8. Benefits of Oral Contraceptives • Reduction of Pregnancies • Reductions of menstrual disorders • Reduction of premenopausal/menopausal symptoms • Reduction of reproductive organ neoplasms • Reduction of reproductive disorders (Pelvic Inflammatory Disease & endometriosis • Reduced incidence of ectopic pregnancies • Other: reduction of acne, anemia, ulcers, rheumatoid arthritis

  9. Pharmacologic effect of Contraceptive Agents

  10. Severe Adverse Effects

  11. Clotting disorders Known cancer Hepatic disorders Diabetes - insulin Pregnancy Age older than 35 years and smoker Migraine Hypertension Varicose veins Cardiac/renal dysfunction Diabetes w/o insulin Hepatitis Hypercholesterolemia Contraindications Relative Contraindications

  12. Postcoital Contraceptives

  13. Progesterone Antagonist: Mifepristone and Ulipristal • Mifepristone, a "19-norsteroid“, that binds strongly to the progesterone receptor and inhibits the activity of progesterone • In the early stage of pregnancy causes detachment of the blastocyst following decrease in hCG and progesterone production, which facilitates expulsion of blastocyst. • is used as postcoitalcontraceptive for termination of early pregnancy with >90% success • limited clinical studies suggest that mifepristone may be useful in the treatment of endometriosis, Cushing's syndrome, breast cancer • Ulipristal, a derivative of 19-norprogesterone, a partial agonist of the progesterone receptor • inhibits LF release and LH-induced follicular rupture, and blocks endometrial implantation of the fertilized egg. • remains effective for 5 days after intercourse.

  14. Pro-fertility agents:Estrogen Inhibitors and Antagonists • tamoxifen, a competitive partial agonist inhibitor of estradiol at the estrogen receptor, • is used in the palliative treatment of breast cancer in postmenopausal women and for chemoprevention of breast cancer in high-risk women; • may increase the risk of endometrial cancer • raloxifene ,estrogen agonist-antagonist, is approved for the prevention of postmenopausal osteoporosis and prophylaxis of breast cancer in women with risk factors. • clomiphene, partial agonist, is used as an ovulation-inducing agent cyclophenanthrene structure triphenylethylene structure benzothiophene structure triphenylethylene structure

  15. Clomiphene • Clomiphene increases the amplitude of LH and FSH pulses without a change in pulse frequency • Clomiphene is used in the treatment of ovulation disorders in patients who wish to become pregnant. It stimulates ovulation in 70% of women. • The compound is of no value in patients with ovarian or pituitary failure. • Clomiphene is also used in men to stimulate gonadotropin release and enhance spermatogenesis • Adverse Effects • hot flushes, headache, constipation, allergic skin reactions, and reversible hair loss • multiple pregnancy is approximately 10%. • Contraindications • enlarged ovaries • treatment with clomiphene for more than a year may be associated with arisk of low-grade ovarian cancer

  16. Other Therapies for Induction of Ovulation Gonadotropins Synthetic GnRHAnalogues

  17. Gonadotropins • Follicle-Stimulating Hormone (FSH) • Urofollitropin (uFSH), is a purified preparation of human FSH that is extracted from the urine of postmenopausal women, • is used to induce ovulation in women with anovulation that is secondary to hypogonadotropichypogonadism, polycystic ovary syndrome, obesity, and other causes and to treat male infertility. • Recombinant forms of FSH (rFSH): follitropin-αandfollitropin-β, are used for controlled ovulation hyperstimulation in women, infertility in men due to hypogonadism • Luteinizing Hormone (LH) • Lutropin-α, the recombinant form of human LH, has only been approved for use in combination with follitropin-αfor stimulation of follicular development in infertile women with profound LH deficiency. • Human Chorionic Gonadotropin (hCG) • Choriogonadotropin -α(rhCG), a recombinant form of hCG, is used for controlled ovulation and hyperstimulation ovarian follicle development in women with hypogonadotropichypogonadism

  18. Ovulation Induction • Gonadotropins are used to induce ovulation in women with anovulation that is secondary to hypogonadotropichypogonadism, polycystic ovary syndrome, obesity. • Gonadotropins are also used for controlled ovarian hyperstimulation in assisted reproductive technology procedures. • Toxicity & Contraindications • the ovarian hyperstimulation syndromein 0.5–4% and multiple pregnancies in15–20% cases. • the ovarian hyperstimulation syndrome is characterized by ovarian enlargement, ascites, hydrothorax, and hypovolemia, sometimes resulting in shock. • headache, depression, edema, precocious puberty, and (rarely) production of antibodies to hCG.

  19. Male Infertility • both LH and FSH are used for treatment of infertility in hypogonadalmen • initial treatment for 8–12 weeks with injections of 1000–2500 IU hCG several times per week following human menopausal gonadotropins (hMG) injection at a dose of 75–150 units three times per week. • lnmen with hypogonadalhypogonadism, it takes an average of 4–6 months of such treatment for sperm to appear in the ejaculate. • an advance that has indirectly benefited gonadotropin treatment of male infertility is intracytoplasmic sperm injection (ICSI), in which a single sperm is injected directly into a mature oocyte that has been retrieved after controlled ovarian hyperstimulation of a female partner.

  20. Regulation of Gonadotropin Synthesis and Secretion • the hypothalamic peptide GnRH is the predominant regulator of gonadotropin synthesis and secretion. • GnRHrelease is pulsatile and is crucial for the proper synthesis and release of the gonadotropins; • the continuous administration of GnRH leads to desensitization and down-regulation of GnRH receptors on pituitary gonadotropes

  21. Structures of GnRH and GnRH Analogs

  22. Synthetic GnRH Agonists • Gonadorelin is an acetate salt of synthetic human GnRH. • Synthetic GnRH analogs: goserelin, histrelin, leuprolide, nafarelin, and triptorelin. • These analogs all have D-amino acids at position 6, and all but nafarelin have ethylamide substituted for glycine at position 10. • Both modifications make them more potent and longer-lasting than native GnRH and gonadorelin.

  23. Therapeutic Uses of Synthetic GnRH Agonists • Female and Male Infertility • Diagnosis of LH Responsiveness • Controlled Ovarian Hyperstimulation • pulsatile intravenous administration of gonadorelin every 1–4 hours stimulates FSH and LH secretion. • continuous administration of gonadorelin or its longer-acting analogs produces a biphasic response. The first 7–10 days, an agonist effect results in increased concentrations of gonadal hormones in males and females. • The continued presence of GnRH results in an inhibitory action that manifests as a drop in the concentration of gonadotropins and gonadal steroids.

  24. Synthetic GnRH Receptor Antagonists • GnRH antagonists are approved for preventing the LH surge during controlled ovarian hyperstimulation. • GnRH antagonists produce an immediate antagonist effect, their use is delayed until day 6–8 of the in vitro fertilization cycle. • Ganirelixand cetrorelixare approved for use in controlled ovarian hyperstimulationprocedures, they inhibit the secretion of FSH and LH in a dose-dependent manner.

  25. Side effects of synthetic fertility drugs • headache • flushing • abdominal discomfort • hot flashes, osteoporosis • vaginal dryness • altered lipid metabolism • multiple births • emotional lability • acne • weight gain • hirsituism

  26. Literature: Bertram G. Katzung, Susan B. Masters, Anthony J. Trevor Basic & Clinical Pharmacology, 11e, Chapter 40. The Gonadal Hormones & Inhibitors Chapter 37 Hypothalamic & Pituitary Hormones

More Related